Investors bought shares of Abbott Laboratories (NYSE:ABT) on weakness during trading on Monday following insider selling activity. $63.82 million flowed into the stock on the tick-up and $30.82 million flowed out of the stock on the tick-down, for a money net flow of $33.00 million into the stock. Of all stocks tracked, Abbott Laboratories had the 7th highest net in-flow for the day. Abbott Laboratories traded down ($0.27) for the day and closed at $55.29Specifically, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $55.00, for a total value of $3,913,635.00. Following the sale, the insider now directly owns 144,955 shares of the company’s stock, valued at approximately $7,972,525. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brian J. Blaser sold 23,866 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $55.55, for a total value of $1,325,756.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 306,786 shares of company stock worth $16,715,522. Insiders own 0.76% of the company’s stock.
Several equities analysts recently issued reports on the company. BidaskClub cut Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Cowen and Company reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research report on Thursday, August 17th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Barclays PLC upped their price objective on Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a research report on Thursday, August 3rd. Seven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $56.81.
The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The firm has a market cap of $96,240.00, a P/E ratio of 23.05, a P/E/G ratio of 2.08 and a beta of 1.55.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were paid a $0.265 dividend. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.92%. Abbott Laboratories’s dividend payout ratio (DPR) is 87.60%.
Large investors have recently bought and sold shares of the company. Villere ST Denis J & Co. LLC increased its stake in shares of Abbott Laboratories by 2.3% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 268,200 shares of the healthcare product maker’s stock worth $13,037,000 after purchasing an additional 5,950 shares in the last quarter. Private Bank & Trust Co. increased its stake in Abbott Laboratories by 12.3% in the 2nd quarter. Private Bank & Trust Co. now owns 30,322 shares of the healthcare product maker’s stock worth $1,473,000 after buying an additional 3,330 shares in the last quarter. Comerica Securities Inc. purchased a new stake in Abbott Laboratories in the 1st quarter worth $2,833,000. AQR Capital Management LLC increased its stake in Abbott Laboratories by 264.8% in the 1st quarter. AQR Capital Management LLC now owns 634,391 shares of the healthcare product maker’s stock worth $28,173,000 after buying an additional 460,477 shares in the last quarter. Finally, Century Capital Management LLC purchased a new stake in Abbott Laboratories in the 1st quarter worth $4,332,000. Hedge funds and other institutional investors own 69.99% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Investors Buy Abbott Laboratories (ABT) on Weakness on Insider Selling” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/20/investors-buy-abbott-laboratories-abt-on-weakness-on-insider-selling.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.